What is the 13F Pro Quality Score for NDRA?

13F Pro ranks ENDRA Life Sciences Inc. (NDRA) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View NDRA's current score at https://13fpro.ai/research/NDRA (free sign-up required for the full ranking).

Where does 13F Pro source NDRA data?

All ENDRA Life Sciences Inc. fundamentals and ownership data come directly from SEC EDGAR. ENDRA Life Sciences Inc. files with the SEC under CIK 1681682. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is NDRA in?

ENDRA Life Sciences Inc. (NDRA) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is NDRA research updated on 13F Pro?

NDRA's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

ENDRA Life Sciences Inc.(NDRA)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1681682 NDRA stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $0.5M in revenue.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

NDRA Stock Analysis & AI Quality Score

AI stock analysis and institutional research for ENDRA Life Sciences Inc. (NDRA), a Healthcare sector company. NDRA is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $0.5m in revenue. Based on the latest XBRL financial filings (Q1 2026), ENDRA Life Sciences Inc. reports net income of $-1.3M, free cash flow of $-1.1M. Top institutional holders of NDRA by reported 13-F value include Altium Capital Management, GEODE CAPITAL MANAGEMENT,, VANGUARD FIDUCIARY CO, based on the most recent SEC filings. NDRA trades on the Nasdaq exchange and files with the SEC under CIK 1681682. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate NDRA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for ENDRA Life Sciences Inc. directly from SEC EDGAR.

Net Income

Q1 2026

$-1.3M

Free Cash Flow

Q1 2026

$-1.1M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

—FY 2025

FY22 —FY23 —FY24 —FY25 —

Net Income

+38.9% YoY

$-7.0MFY 2025

FY22 $-13.2MFY23 $-10.1MFY24 $-11.5MFY25 $-7.0M

Operating Income

+46.7% YoY

$-5.8MFY 2025

FY22 $-13.2MFY23 $-10.5MFY24 $-10.8MFY25 $-5.8M

EPS (Diluted)

+84.3% YoY

$-8.93FY 2025

FY22 —FY23 $-2766.85FY24 $-56.94FY25 $-8.93

Total Assets

-13.4% YoY

$3.9MFY 2025

FY22 $9.3MFY23 $6.8MFY24 $4.5MFY25 $3.9M

Total Debt

—FY 2025

FY22 $28.5KFY23 $28.5KFY24 $0.00FY25 —

Op. Cash Flow

+30.0% YoY

$-5.2MFY 2025

FY22 $-12.8MFY23 $-9.5MFY24 $-7.4MFY25 $-5.2M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	—	—	—	—	—	$0.00
Net Income	$-7.0M +38.9%	$-11.5M -14.4%	$-10.1M +23.7%	$-13.2M -17.3%	$-11.2M +4.2%	$-11.7M
Operating Income	$-5.8M +46.7%	$-10.8M -2.8%	$-10.5M +20.0%	$-13.2M -14.4%	$-11.5M +0.0%	$-11.5M
EPS (Diluted)	$-8.93 +84.3%	$-56.94 +97.9%	$-2766.85	—	—	—
Total Assets	$3.9M -13.4%	$4.5M -34.1%	$6.8M -27.2%	$9.3M -28.0%	$12.9M +46.9%	$8.8M
Total Debt	—	$0.00 -100.0%	$28.5K +0.0%	$28.5K -94.8%	$546.6K	—
Operating Cash Flow	$-5.2M +30.0%	$-7.4M +22.5%	$-9.5M +25.2%	$-12.8M -14.8%	$-11.1M -3.5%	$-10.7M

AI Insight: NDRA Financial Trends

ENDRA remains pre-revenue with persistent quarterly losses; equity base eroded from $9M to $2M over 2 years.

• No revenue generation across all periods. Net losses ranged $1M–$4M quarterly; Q4 2024 saw peak loss of $4M.

• Operating cash flow negative every quarter, $1M–$2M outflow; no sign of cash generation or path to profitability.

• Shareholder equity collapsed 78% from Q2 2024 ($9M) to Q1 2026 ($2M), reflecting cumulative losses.

⚠ Q4 2025 net loss spiked to $3M after two quarters of $1M–$2M losses. Deterioration warrants monitoring.

⚠ Equity now $2M; continued quarterly burn at $1M–$3M poses immediate runway risk without capital injection or revenue inflection.

AI Insight: NDRA Ratio Trends

Insufficient data to assess trend; only Q2–Q3 2024 show metrics, both deeply negative, with all subsequent quarters blank.

• Q2 2024 ROE and ROA both severely negative at -99.1% and -85.4%, indicating substantial net losses relative to equity and assets.

• Q3 2024 ROE deteriorated further to -142.6%; ROIC remained deeply negative at -91.4%.

• Debt-to-equity remained 0.00 across all reported quarters, indicating no financial leverage.

⚠ All metrics from Q4 2024 onward are blank; unable to assess whether losses have stabilized or cash position remains viable.

Get alerted when NDRA's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for ENDRA Life Sciences Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of NDRA

Altium Capital Management LP
$241.3K51,900 sh
GEODE CAPITAL MANAGEMENT, LLC
$98.0K21,078 sh
VANGUARD FIDUCIARY TRUST CO
$47.1K10,121 sh
MORGAN STANLEY
$16.5K3,546 sh
VANGUARD CAPITAL MANAGEMENT LLC
$13.1K2,816 sh
UBS Group AG
$707.00152 sh
NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO
$88.0019 sh
Caitong International Asset Management Co., Ltd
$19.004 sh

Fund	Value	Shares
Altium Capital Management LP	$241.3K	51,900
GEODE CAPITAL MANAGEMENT, LLC	$98.0K	21,078
VANGUARD FIDUCIARY TRUST CO	$47.1K	10,121
MORGAN STANLEY	$16.5K	3,546
VANGUARD CAPITAL MANAGEMENT LLC	$13.1K	2,816
UBS Group AG	$707.00	152
NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO	$88.00	19
Caitong International Asset Management Co., Ltd	$19.00	4

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put NDRA on your watchlist

Track score changes the day ENDRA Life Sciences Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is NDRA a good stock to buy?

13F Pro's AI-powered analysis of ENDRA Life Sciences Inc. (NDRA) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for NDRA are available on the NDRA stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own NDRA?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling NDRA. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of ENDRA Life Sciences Inc.'s investment landscape.